RUBY
NCT02505048
A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
Status:
Recruiting
II
Phase
Line of Therapy
Advanced / Metastatic
Disease Stage
Biomarker(s)
BRCA1/2
Investigational
Product
Rucaparib
Treatment Arms
o Experimental: rucaparib